Skip to main content
ASSURE TECH (HANGZHOU) CO., LTD. logo

ASSURE TECH (HANGZHOU) CO., LTD. — Investor Relations & Filings

Ticker · 688075 ISIN · CNE100004ZC0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2024-11-04 Notice of Dividend Amou…
Country CN China
Listing Shanghai Stock Exchange 688075

About ASSURE TECH (HANGZHOU) CO., LTD.

https://www.diareagent.com/

Assure Tech (Hangzhou) Co., Ltd. is a biotechnology enterprise specializing in the research, development, and manufacturing of in vitro diagnostic (IVD) reagents and clinical testing instruments. The company focuses on rapid diagnostic tests and Point of Care Testing (POCT) solutions across various medical fields, including infectious diseases, drug of abuse screening, oncology, cardiac markers, and fertility. Utilizing advanced lateral flow immunoassay technology, Assure Tech provides diagnostic tools designed for accuracy and efficiency in clinical and laboratory settings. The company adheres to international quality standards, maintaining ISO 13485 certification and obtaining regulatory clearances such as FDA and CE marks for its product range. Through its integrated R&D and production infrastructure, Assure Tech supplies a diverse portfolio of diagnostic products to a global customer base.

Recent filings

Filing Released Lang Actions
安旭生物2024年半年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement from Hangzhou Anxu Biotechnology Co., Ltd. regarding the distribution of cash dividends for the 2024 half-year period. It details the dividend per share, relevant dates (record date, ex-dividend date, payment date), the shareholder meeting approving the distribution, tax treatment for different shareholder categories, and contact information for inquiries. The document is focused on dividend amount and payment details rather than financial results or comprehensive reports. It is not a full financial report, earnings release, or management discussion. The content matches the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and related details for shareholders.
2024-11-04 Chinese
安旭生物关于召开2024年第三次临时股东大会的通知
Regulatory Filings Classification · 95% confidence The document is a notice about convening the 2024 third extraordinary general meeting of shareholders (临时股东大会) for Hangzhou Anxu Biotechnology Co., Ltd. It details the meeting date, voting methods, agenda items, registration procedures, and proxy authorization. There is no financial data, earnings information, or report content. It is an announcement related to a shareholder meeting, specifically a notice of the meeting itself, not the results or materials of the meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) only if it contains voting results, but this document is a notice of the meeting, not voting results. It is not an AGM Information (AGM-R) because it is not the presentation or materials shared during the AGM but a notice of the meeting. The best fit is Regulatory Filings (RNS) as a general regulatory announcement about the shareholder meeting. The document length is short (3101 characters), and it is a formal announcement of the meeting, not a report or transcript. Hence, classify as Regulatory Filings (RNS).
2024-10-30 Chinese
民生证券股份有限公司关于杭州安旭生物科技股份有限公司部分募投项目变更资金用途及延期事项的核查意见
Regulatory Filings
2024-10-30 Chinese
安旭生物2024年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2024 年第三季度报告' which translates to '2024 Third Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the third quarter of 2024. The document explicitly states it is a quarterly report and includes unaudited financial statements for the period ending September 30, 2024. The length of the document (13,388 characters) and the presence of comprehensive financial data confirm it is a substantive financial report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q3 2024
2024-10-30 Chinese
安旭生物关于继续使用超募资金及部分闲置募集资金进行现金管理的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Hangzhou Anxu Biotechnology Co., Ltd. regarding the continued use of excess raised funds and some idle raised funds for cash management. It includes specifics about the board meetings approving the use of these funds, investment purposes, types of investment products, investment limits and terms, risk control measures, and opinions from the supervisory board and the sponsoring institution. The document is regulatory in nature, focusing on the management and use of raised funds rather than presenting financial statements or earnings results. It does not contain financial statements or quarterly/yearly financial performance data, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a simple announcement of a report publication, nor is it a certification or insider dealing report. The content fits best under Regulatory Filings (RNS) as it is a regulatory disclosure about fund management and usage compliance, which does not fit other more specific categories.
2024-10-30 Chinese
安旭生物第二届监事会第十四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Hangzhou Anxu Biotechnology Co., Ltd. It details the meeting held on October 29, 2024, where the board reviewed and approved the company's 2024 third quarter report, use of surplus raised funds for cash management, and changes in the use and extension of some fundraising projects. The document explicitly states that the detailed 2024 third quarter report is disclosed separately on the Shanghai Stock Exchange website, indicating this document is not the report itself but a meeting resolution and announcement related to it. The document length is short (1538 characters), and it serves as an official announcement of board decisions rather than containing substantive financial data or the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and disclosure of board resolutions related to financial reports and fund usage, rather than an Interim/Quarterly Report (IR) or Annual Report (10-K).
2024-10-30 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.